Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs
Defence Therapeutics (OTCQB:DTCFF) presented new preclinical data on its proprietary Accum platform at the 16th World ADC Conference in San Diego (November 4-5, 2025).
Presenters said Accum enhanced intracellular delivery and payload release in ADCs, improving potency and therapeutic index in the data shown. Defence announced plans to expand collaborative and internal testing of Accum across multiple commercial and clinical-stage ADC constructs to evaluate plug-and-play applicability across different antibodies and payloads.
The company indicated active engagement with industry partners to accelerate evaluations and explore potential benefits for targeted cancer therapies.
Defence Therapeutics (OTCQB:DTCFF) ha presentato nuovi dati preclinici sulla sua piattaforma proprietaria Accum al 16° World ADC Conference di San Diego (4-5 novembre 2025).
I relatori hanno detto che Accum ha potenziato la somministrazione intracellulare e il rilascio del payload negli ADC, migliorando la potenza e l indice terapeutico nei dati mostrati. Defence ha annunciato piani per espandere i test collaborativi e interni di Accum su molteplici costrutti ADC commerciali e a livello clinico per valutare l'applicabilità plug-and-play tra diversi anticorpi e payload.
L'azienda ha indicato un coinvolgimento attivo con partner del settore per accelerare le valutazioni e esplorare potenziali benefici per terapie mirate contro il cancro.
Defence Therapeutics (OTCQB:DTCFF) presentó nuevos datos preclínicos sobre su plataforma propietaria Accum en la 16ª World ADC Conference en San Diego (4-5 de noviembre de 2025).
Los ponentes dijeron que Accum mejoró la entrega intracelular y la liberación de la carga en los ADC, mejorando la potencia y el índice terapéutico en los datos mostrados. Defence anunció planes para ampliar las pruebas colaborativas e internas de Accum en múltiples constructos de ADC comerciales y en etapas clínicas para evaluar la aplicabilidad plug-and-play entre diferentes anticuerpos y cargas.
La empresa indicó un compromiso activo con socios de la industria para acelerar las evaluaciones y explorar posibles beneficios para terapias dirigidas contra el cáncer.
Defence Therapeutics (OTCQB:DTCFF)는 16번째 World ADC Conference를 샌디에이고에서(2025년 11월 4-5일) 자사 특허 플랫폼 Accum에 대한 새로운 전임상 데이터를 발표했습니다.
발표자들은 Accum이 ADC에서 세포 내 전달 및 payload 방출을 향상시켜 데이터에서 효능과 치료 지표를 개선했다고 말했습니다. Defence는 서로 다른 항체와 payload에 대해 Plug-and-Play 적용 가능성을 평가하기 위해 상업적 및 임상 단계 ADC 구성에 걸친 Accum의 협력 및 내부 테스트를 확장할 계획을 발표했습니다.
회사는 평가를 가속하고 표적 암 치료에 대한 잠재적 이점을 탐색하기 위해 업계 파트너와의 적극적인 협력을 언급했습니다.
Defence Therapeutics (OTCQB:DTCFF) a présenté de nouvelles données précliniques sur sa plate-forme propriétaire Accum lors de la 16e World ADC Conference à San Diego (4-5 novembre 2025).
Les présentateurs ont déclaré que Accum avait amélioré la délivrance intracellulaire et la libération de la charge utile dans les ADC, améliorant la puissance et l’indice thérapeutique dans les données montrées. Defence a annoncé des plans pour étendre les tests collaboratifs et internes d'Accum sur plusieurs constructions ADC commerciales et en stade clinique afin d’évaluer l’applicabilité plug-and-play entre différents anticorps et charges utiles.
L’entreprise a indiqué un engagement actif avec des partenaires de l’industrie pour accélérer les évaluations et explorer les avantages potentiels pour les thérapies ciblées contre le cancer.
Defence Therapeutics (OTCQB:DTCFF) präsentierte neue präklinische Daten zu seiner proprietären Accum-Plattform auf der 16. World ADC Conference in San Diego (4.–5. November 2025).
Die Referenten sagten, dass Accum die intrazelluläre Lieferung und Freisetzung der Payload in ADCs verbessert habe, wodurch Potenz und therapeutischer Index in den gezeigten Daten verbessert wurden. Defence kündigte Pläne an, die kolaborativen und internen Tests von Accum über mehrere kommerzielle und klinische ADC-Konstrukte hinweg zu erweitern, um die Plug-and-Play-Anwendbarkeit über verschiedene Antikörper und Payloads zu bewerten.
Das Unternehmen gab ein aktives Engagement mit Branchenpartnern an, um Bewertungen zu beschleunigen und potenzielle Vorteile für zielgerichtete Krebstherapien zu erkunden.
Defence Therapeutics (OTCQB:DTCFF) قدمت بيانات ما قبل السريرية الجديدة حول منصتها الملكية Accum في المؤتمر العالمي السادس عشر World ADC في سان دييغو (4-5 نوفمبر 2025).
قال مقدمو العرض إن Accum حسّن التوصيل داخل الخلايا وإطلاق الحمولة في ADCs، مما حسّن الفعالية والمؤشر العلاجي في البيانات المعروضة. أعلنت Defence عن خطط لتوسيع الاختبارات التعاونية والداخلية لـAccum عبر عدة التركيبات التجارية والمرحلة السريرية لـ ADC لتقييم قابلية التوصيل والتشغيل بين أجسام مضادة مختلفة والحمولات.
وأشارت الشركة إلى تفاعل نشط مع شركاء الصناعة لتسريع التقييمات واستكشاف الفوائد المحتملة للعلاجات المستهدفة للسرطان.
- None.
- None.
Montreal, Quebec--(Newsfile Corp. - November 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), is pleased to announce the successful presentation of new data on its proprietary Accum® platform at the 16th World ADC Conference in San Diego, USA (November 4-5, 2025).
The presentation generated exceptional interest from both the scientific and industry communities, with attendees continuing discussions around Defence's poster long after the official session concluded. The results presented by Dr. Maxime Parisotto, Chief Scientific Officer of Defence Therapeutics, demonstrated how Accum® enhances intracellular delivery and payload release, thereby amplifying the potency and therapeutic index of ADCs.
"The response to our new data was phenomenal," said Dr. Parisotto. "It's clear that the Accum® platform addresses one of the key challenges in ADC design-efficient endosomal escape and payload delivery. We are now moving forward to test Accum® across a broader range of on-market and development-stage ADCs to fully explore its potential to improve efficacy and patient outcomes."
The Company is now expanding its collaborative and internal testing programs to include multiple commercial and clinical-stage ADC constructs, aiming to validate Accum® as a plug-and-play enhancer for the next generation of targeted cancer therapies.
"Our goal is to demonstrate that Accum® can universally enhance the performance of ADCs, regardless of the payload or antibody used," said Dr. Mark Lambermon, Head of Quality and Operation at Defence Therapeutics, who was also in attendance in San Diego. "We are engaging with leading industry partners to accelerate these evaluations and bring this transformative technology closer to patients."
The Defence team extends its gratitude to the organizers of the World ADC Conference and to the many collaborators and industry partners who joined discussions in San Diego.
For partnership inquiries or to learn more about Defence's expanding ADC development initiatives, please contact:
info@defencetherapeutics.com
www.defencetherapeutics.com
About Defence:
Defence Therapeutics is a publicly-traded biotechnology company developing and engineering the next generation of ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273393
FAQ
What did Defence Therapeutics (DTCFF) present at the World ADC Conference on November 4-5, 2025?
How is Defence (DTCFF) expanding Accum testing after the November 6, 2025 announcement?
Does Defence report clinical approvals or financial results related to Accum in this November 6, 2025 release?
Which Defence executives presented Accum data at the World ADC Conference in San Diego?
What is the stated goal of Defence's expanded Accum evaluations for investors following the November 6, 2025 release?
How can potential partners contact Defence about Accum collaboration after the November 6, 2025 announcement?
